Bharat Biotech's Ankleshwar plant gets government’s approval for manufacturing Covaxin
The Minister said that this move will help ramp up availability of the indigenous vaccine to speed up the national vaccination drive.
FollowUnion minister of health and family welfare Mansukh Mandaviya took to Twitter on Tuesday and announced that the government has approved Bharat Biotech's Covaxin manufacturing facility in Gujarat’s Ankleshwar.
“Govt of India approves vaccine manufacturing facility for production of Bharat Biotech’s Covaxin in Ankleshware, Gujarat,” Mandaviya tweeted.
“Following PM Narendra Modiji’s vision of SabkoVacccineMuftVaccine, this will increase vaccine availability & accelerate the world’s largest vaccine drive,” the Health Minister added.
The Minister said that this move will help ramp up availability of the indigenous vaccine to speed up the national vaccination drive.
In May this year, Bharat Biotech had announced that it plans to produce an additional 200 million doses of Covaxin at its subsidiary's Ankleshwar-based facility. The Hyderabad-based firm had noted that it would utilise the manufacturing plant of its wholly-owned unit - Chiron Behring, to add another 200 million doses of Covaxin.
Earlier, NITI Aayog member (Health) Dr V K Paul told reporters on August 3 that IIL has started an additional facility at Ankleshwar in Gujarat where 60 lakh doses of the vaccine will be manufactured.
Bharat Biotech in a statement had said that it commenced manufacturing Covaxin at Ankleshwar and the Malur unit near Bengaluru from early June, prior to which it executed engineering batches to study the equipment functionality.
The facility at Ankleshwar was acquired by Bharat Biotech in early 2019 from GlaxoSmithKline Asia as part of its acquisition of Chiron Behring Vaccines Pvt Ltd.
NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona
